CAsting and REhabilitation Versus Supervised Neglect for Osteochondral Lesions of the Talus in the Pediatric Population
Launched by TRISTAN BUCK · Jan 13, 2024
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best way to treat children with a specific type of ankle injury called an osteochondral lesion of the talus (OCL). This injury can cause pain, especially when the child is walking or running. The researchers want to find out if a treatment involving casting and rehabilitation is more effective than the usual method, which they refer to as "skill-full neglect." In the trial, one group of children will wear a cast and use crutches for eight weeks, followed by supervised physical therapy. The other group will receive standard care without the cast.
To be part of the study, children must be between 4 and 18 years old and have been diagnosed with an OCL through a special CT scan. They should also have an open growth plate in their leg, which means their bones are still growing. Children with recent severe injuries or certain medical conditions will not be eligible. Participants will need to fill out some questionnaires about their pain and quality of life, but the main focus is on helping them recover from their injuries. The trial is not yet recruiting participants, but it aims to improve treatment options for young patients dealing with this challenging condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic, osteochondral lesion of the talus
- • Diagnosed on Computed Tomography (CT)
- • Open physes of the distal tibia confirmed by a specialized musculoskeletal or pediatric radiologist
- • Age ≥4 and ≤18
- Exclusion Criteria:
- • acute traumatic lesions
- • surgically treated OLTs
- • systemic diseases that can influence cartilage conditions (such as hemophilia)
About Tristan Buck
Tristan Buck is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial designs and rigorous scientific methodologies. With a focus on enhancing therapeutic options across various disease states, the organization prioritizes ethical standards and regulatory compliance while fostering collaboration with healthcare professionals, researchers, and stakeholders. By leveraging cutting-edge technology and data analytics, Tristan Buck aims to streamline the clinical trial process, ensuring that new treatments are both effective and safe for patients. Their mission is to drive progress in the healthcare landscape, ultimately contributing to the development of life-changing therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Breda, , Netherlands
Amsterdam, , Netherlands
Breda, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported